Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Scheibelhoffer

Facial Plastic Surgery Wayne, NJ Medical Doctor

NPI 1194764712 CMS profile 190236

1211 Hamburg Tpke, Suite 205, Wayne, NJ 07470

Open in the dashboard

General payments

$3,610

209 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Scheibelhoffer of Wayne, NJ is reported in the CMS Open Payments database as having received $3,610 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $934 51
2024 General $843 48
2023 General $880 55
2022 General $562 33
2021 General $132 9
2020 General $70 3
2019 General $189 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Scheibelhoffer
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to John Scheibelhoffer were reported at $934. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year John Scheibelhoffer Facial Plastic Surgery median Middle half National median
2019 $189 $225 $92–$651 $163
2020 $70 $132 $45–$323 $114
2021 $132 $186 $67–$558 $132
2022 $562 $218 $83–$594 $149
2023 $880 $237 $94–$564 $160
2024 $843 $233 $104–$575 $164
2025 $934 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $951 56 payments
  2. GlaxoSmithKline, LLC. $498 34 payments
  3. OptiNose US, Inc. $363 22 payments
  4. Aerin Medical Inc. $333 13 payments
  5. Regeneron Healthcare Solutions, Inc. $290 17 payments
  6. CSL Behring $270 15 payments
  7. kaleo, Inc. $229 15 payments
  8. Stryker Corporation $99 3 payments
  9. ALK-Abello, Inc $73 5 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $64 4 payments
  11. Other $441 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,610 209 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $1,395 85 payments
  2. NUCALA $444 30 payments
  3. Xhance $363 22 payments
  4. DUPIXENT Inflammation And Immunology $238 14 payments
  5. RHINAER STYLUS $209 7 payments
  6. VIVAER STYLUS $209 7 payments
  7. Haegarda $208 12 payments
  8. AUVI-Q Allergy $145 10 payments
  9. AUVI-Q Allergy $83 5 payments
  10. Odactra $73 5 payments
  11. Other $863 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

430

Median for Otolaryngology: 297

Drug cost

$10,376

Median for Otolaryngology: $6,314

Branded share of claims

24.7%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mometasone Furoate Generic 24 $2,882
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 27 $2,798
Fluocinolone Acetonide Oil Generic 45 $1,483
Fluticasone Propionate Generic 30 $632
Methylprednisolone Generic 98 $598
Cefuroxime Cefuroxime Axetil Brand 38 $562
Azelastine Hcl Generic 19 $493
Montelukast Sodium Generic 15 $356
Prednisone Generic 47 $174
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 20 $158

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$223,119

Of which drugs: $232

Medicare patients

936

Average age 76

Services billed

4,910

564 women, 372 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 36%
Diabetes 26%
Atrial fibrillation 20%
Osteoporosis 20%
Chronic kidney disease 19%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 53 2,288 $229

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $269
  • Regeneron Healthcare Solutions, Inc. $111
$380 — —
Xhance
  • OptiNose US, Inc. $125
$125 — —
NUCALA
  • GlaxoSmithKline, LLC. $94
$94 — —
AUVI-Q
  • kaleo, Inc. $83
$83 — —
Haegarda
  • CSL Behring $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Facial Plastic Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record